summary of the Study: Smartwatches for Atrial Fibrillation (AF) Detection
This study investigated the effectiveness of using smartwatches with photoplethysmography and single-lead ECG functionality for screening patients at high risk of stroke due to potential atrial fibrillation (AF).
Key Findings:
* Earlier AF Detection: Smartwatches detected new-onset AF in 9.6% of participants, compared to 2.3% in the standard care group. This difference was statistically significant (p = .001).
* number Needed to Screen: Only 14 patients need to be screened with a smartwatch to detect one new case of AF.
* Asymptomatic AF: The smartwatch detected AF in several patients who were unaware of their arrhythmia.
* Treatment Initiation: All patients diagnosed with new-onset AF started anticoagulant therapy.
* No Difference in Major CV Events: There was no significant difference in major cardiovascular events between the two groups after the trial period.
* Potential Cost Savings: Researchers believe the benefits of earlier diagnosis and stroke prevention could offset the cost of the smartwatches.
Study Details:
* Participants: 437 older patients (median age 75, 47% women) with a high risk of stroke (based on CHA2DS2-VASc score).
* Groups: Participants were randomly assigned to either 6 months of smartwatch monitoring or standard care (12-lead ECG, Holter monitoring, etc.).
* Smartwatch Use: Participants in the smartwatch group wore the watch at least 12 hours a day and recorded a 30-second ECG when experiencing symptoms or receiving an irregularity notification.
* ECG Adjudication: ecgs from the smartwatch were reviewed by a dedicated team within 24 hours.
the study suggests that smartwatches can be a valuable tool for early detection of AF in high-risk patients, perhaps leading to faster treatment and reduced stroke risk.
